The study aims to assess the effectiveness of using immune cell serum replacement (SR) to induce cytokine-induced killer (CIK) cells from peripheral blood mononuclear cells (PBMNC) for large-scale immune cell production.
The research involved culturing PBMNC from healthy individuals after cryopreservation, measuring cell viability and determining the effectiveness of different concentrations of SR compared to fresh cells.
Results showed that 5% SR can replace autologous plasma without harming cell proliferation or function, supporting its use in cryopreserved PBMNC-based cell therapies.